Derivatives 6,7,8,9-tetrahydro-5H-pyrimido [4,5-d] azepin-4-yl] -amine as TRPV1 modulators for the treatment of pain.

A compound of formula (I): wherein: R1 is -H; -NRaRb; OH; C1-6 -alkyl, -OC 1-6 alkyl, -O- (saturated monocyclic cycloalkyl), -O-C1- alkyl (saturated monocyclic cycloalkyl), -O- (saturated monocyclic heterocycloalkyl), -O-phenyl , -O-benzyl, -S-C1-6alkyl, -S- (saturated monocyclic cycloalkyl), -S-C1- alkyl (saturated monocyclic cycloalkyl), -S- (saturated monocyclic heterocycloalkyl), -S-phenyl, -S- benzyl or -SO2-C1-6alkyl unsubstituted or substituted with one or two moieties independently selected from the group consisting of C1-6 alkyl substituents, -OH, C1-4alkyl, halo -NReRf and -O-alkyl; or a phenyl, monocyclic cycloalkyl or monocyclic heteroaryl unsubstituted or substituted with C1-6 -alkyl substituent, -OH, -OC 1-4 alkyl, halo or -NReRf; wherein Ra and Rb are each independently -H; -C1-6alkyl; -C2-3 alkyl group substituted with one -OH substituent, C1-4, -NRcRd or halo -O-alkyl; or a cycloalkyl group monocyclic saturated, C1- -alkyl (saturated monocyclic cycloalkyl), saturated monocyclic heterocycloalkyl, C1- -alkyl (saturated monocyclic heterocycloalkyl), phenyl, benzyl or -alkyl C1- (monocyclic heteroaryl) unsubstituted or substituted with one, two or three moieties independently selected from the group consisting of C1-6 alkyl substituents, -OH, -OC 1-4 alkyl, -NRpRq and halo; or Ra and Rb, taken together with their nitrogen of attachment form a saturated monocyclic or bicyclic heterocycloalkyl group bridge heterocycloalkyl unsubstituted or substituted with one, two or three moieties independently selected from the group consisting of C1-6 alkyl substituents, - C1-4 alkyl-OH, -C 1-2 alkyl-O-C1-2 alkyl, -OH, C1-4, -NRpRq, halogen, -CO2H, and benzyl -O-alkyl; wherein Rc and Rd are each independently -H or -C1-6alkyl; or Rc and Rd, taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl; wherein p and R q are each independently -H or -C1-6alkyl; or p and R q taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl; wherein Re and Rf are each independently -H or -C1-6alkyl; or Re and Rf taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl; R2 is -H or -C1-6alkyl; R3 is a monocyclic cycloalkyl group, phenyl, benzyl, phenethyl, indanyl, thiazolyl, thiophenyl, pyridyl, pyridylmethyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl unsubstituted or substituted with one, two or three substituents Rg ; wherein each Rg substituent is -C1-6alkyl; -C1-4alkyl-OH unsubstituted or substituted with -CF3; cycloalkyl monocyclic saturated; OH; -OC 1-6 alkyl; phenoxy; --CN; -NO 2; -N (Rh) Ri; -C1-4alkyl-N (R) Ri; -C (O) N (Rh) Ri; - N (Rh) C (O) Ri; -N (Rh) SO2-C1-6 alkyl; -C (O) C1-6 alkyl; -S (O) 0-2-C1-6alkyl; -SO2CF3; -SO2N (Rh) Ri; -SCF3; halo; -CF3; -OCF3; -CO2H; C1-6 -CO 2 -alkyl; -C (Rj) (Rx) -CN; -C (Rj) (Rx) -OH; -C (Rj) (Rx) -CO2-C1-6 alkyl; -C (Rj) (Rx) - CO2H; -C (Ri) (Rx) -C (O) N (Rh) Ri; phenyl; or monocyclic heteroaryl; or two adjacent substituents Rg taken together form -O-C1-2alkyl-O-; wherein Ri and Rh are each independently -H or -C1-6alkyl; or Rh and Ri (when both are present) taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl group; Rj is independently -H, -C1-6alkyl or -CF3; Rx is -H or -C1-6alkyl; or Ri and Rx taken together with the carbon to which they are attached form a monocyclic cycloalkyl ring;